Format

Send to

Choose Destination
Eur Urol. 2008 Jun;53(6):1194-201. Epub 2007 Nov 5.

First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer.

Author information

1
Department of Urology, University of Regensburg, St Josef Hospital, Regensburg, Germany. blana@caritasstjosef.de <blana@caritasstjosef.de>

Abstract

OBJECTIVE:

To evaluate the long-term efficacy of high-intensity focused ultrasound (HIFU) therapy for patients with localised prostate cancer.

MATERIAL AND METHODS:

Patients included in this multicentre analysis had T1-T2 NxM0 prostate cancer, a PSA<15 ng/ml, and a Gleason score (GS) < or = 7, and were treated with prototypes or first-generation Ablatherm HIFU devices between October 1997 and August 2001. The Phoenix definition of biochemical failure was used (PSA nadir+2). Treatment failure was defined as: biochemical failure or positive biopsy.

RESULTS:

A total of 140 patients with a mean (SD) age 69.1 yr (6.6) were included. Mean (SD) follow-up was 6.4 yr (1.1). Control prostate biopsies were negative in 86.4% of patients. Median PSA nadir of 0.16 ng/ml (range, 0.0-9.1) was achieved at a mean (SD) of 4.9 mo (5.2). A PSA nadir < or = 0.5 ng/ml was recorded in 68.4% of patients. The actuarial biochemical failure-free survival rates (SR) at 5 and 7 yr were 77% and 69%, respectively. The actuarial disease-free SR at 5 and 7 yr were 66% and 59%, respectively.

CONCLUSIONS:

This study demonstrates the effective long-term cancer control achieved with HIFU in patients with low- or intermediate-risk localised prostate cancer.

PMID:
17997026
DOI:
10.1016/j.eururo.2007.10.062
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center